Crystal Structure of HLA-DP2 and Implications for Chronic Beryllium Disease

Overview

Journal Proc Natl Acad Sci U S A

Specialty Science

Date 2010 Apr 2

PMID 20356827

Citations 57

Authors

Shaodong Dai

Guinevere A Murphy

Frances Crawford

Douglas G Mack

Michael T Falta

Philippa Marrack

John W Kappler

Andrew P Fontenot

Affiliations

Soon will be listed here.

Abstract

Chronic beryllium disease (CBD) is a fibrotic lung disorder caused by beryllium (Be) exposure and is characterized by granulomatous inflammation and the accumulation of Be-responsive CD4(+) T cells in the lung. Genetic susceptibility to CBD has been associated with certain alleles of the MHCII molecule HLA-DP, especially HLA-DPB1*0201 and other alleles that contain a glutamic acid residue at position 69 of the beta-chain (betaGlu69). The HLA-DP alleles that can present Be to T cells match those implicated in the genetic susceptibility, suggesting that the HLA contribution to disease is based on the ability of those molecules to bind and present Be to T cells. The structure of HLA-DP2 and its interaction with Be are unknown. Here, we present the HLA-DP2 structure with its antigen-binding groove occupied by a self-peptide derived from the HLA-DR alpha-chain. The most striking feature of the structure is an unusual solvent exposed acidic pocket formed between the peptide backbone and the HLA-DP2 beta-chain alpha-helix and containing three glutamic acids from the beta-chain, including betaGlu69. In the crystal packing, this pocket has been filled with the guanidinium group of an arginine from a neighboring molecule. This positively charged moiety forms an extensive H-bond/salt bridge network with the three glutamic acids, offering a plausible model for how Be-containing complexes might occupy this site. This idea is strengthened by the demonstration that mutation of any of the three glutamic acids in this pocket results in loss of the ability of DP2 to present Be to T cells.

Citing Articles

Interleukin-1 signaling and CD4 T cells control B cell recruitment to the lungs in chronic beryllium disease.

Gaballa J, Valdez C, Mack D, Minhajuddin F, Raza M, Mohammad T Front Immunol. 2025; 16:1479348.

PMID: 39935485 PMC: 11810750. DOI: 10.3389/fimmu.2025.1479348.

Population genetic dissection of HLA-DPB1 amino acid polymorphism to infer selection.

Mack S, Single R, Solberg O, Thomson G, Erlich H Hum Immunol. 2024; 85(6):111151.

PMID: 39413638 PMC: 11827675. DOI: 10.1016/j.humimm.2024.111151.

Non-overlapping epitopes on the gHgL-gp42 complex for the rational design of a triple-antibody cocktail against EBV infection.

Hong J, Zhong L, Liu L, Wu Q, Zhang W, Chen K Cell Rep Med. 2023; 4(11):101296.

PMID: 37992686 PMC: 10694767. DOI: 10.1016/j.xcrm.2023.101296.

HLA-II immunopeptidome profiling and deep learning reveal features of antigenicity to inform antigen discovery.

Strazar M, Park J, Abelin J, Taylor H, Pedersen T, Plichta D Immunity. 2023; 56(7):1681-1698.e13.

PMID: 37301199 PMC: 10519123. DOI: 10.1016/j.immuni.2023.05.009.

A combination of HLA-DP α and β chain polymorphisms paired with a SNP in the DPB1 3' UTR region, denoting expression levels, are associated with atopic dermatitis.

Margolis D, Duke J, Mitra N, Berna R, Hoffstad O, Wasserman J Front Genet. 2023; 14:1004138.

PMID: 36911412 PMC: 9995861. DOI: 10.3389/fgene.2023.1004138.

References

Fontenot A, Canavera S, Gharavi L, Newman L, Kotzin B . Target organ localization of memory CD4(+) T cells in patients with chronic beryllium disease. J Clin Invest. 2002; 110(10):1473-82. PMC: 151812. DOI: 10.1172/JCI15846. View

McCanlies E, Ensey J, Schuler C, Kreiss K, Weston A . The association between HLA-DPB1Glu69 and chronic beryllium disease and beryllium sensitization. Am J Ind Med. 2004; 46(2):95-103. DOI: 10.1002/ajim.20045. View

Stern L, Brown J, Jardetzky T, Gorga J, Urban R, Strominger J . Crystal structure of the human class II MHC protein HLA-DR1 complexed with an influenza virus peptide. Nature. 1994; 368(6468):215-21. DOI: 10.1038/368215a0. View

Fontenot A, Keizer T, McCleskey M, Mack D, Meza-Romero R, Huan J . Recombinant HLA-DP2 binds beryllium and tolerizes beryllium-specific pathogenic CD4+ T cells. J Immunol. 2006; 177(6):3874-83. DOI: 10.4049/jimmunol.177.6.3874. View

Kreiss K, Mroz M, Zhen B, Martyny J, Newman L . Epidemiology of beryllium sensitization and disease in nuclear workers. Am Rev Respir Dis. 1993; 148(4 Pt 1):985-91. DOI: 10.1164/ajrccm/148.4_Pt_1.985. View

Berretta F, Butler R, Diaz G, Sanarico N, Arroyo J, Fraziano M . Detailed analysis of the effects of Glu/Lys beta69 human leukocyte antigen-DP polymorphism on peptide-binding specificity. Tissue Antigens. 2003; 62(6):459-71. DOI: 10.1046/j.1399-0039.2003.00131.x. View

Todd J, Acha-Orbea H, Bell J, Chao N, Fronek Z, Jacob C . A molecular basis for MHC class II--associated autoimmunity. Science. 1988; 240(4855):1003-9. DOI: 10.1126/science.3368786. View

Wang Z, White P, Petrovic M, Tatum O, Newman L, Maier L . Differential susceptibilities to chronic beryllium disease contributed by different Glu69 HLA-DPB1 and -DPA1 alleles. J Immunol. 1999; 163(3):1647-53. View

Diaz G, Canas B, Vazquez J, Nombela C, Arroyo J . Characterization of natural peptide ligands from HLA-DP2: new insights into HLA-DP peptide-binding motifs. Immunogenetics. 2004; 56(10):754-9. DOI: 10.1007/s00251-004-0735-5. View

10.

Jones E, Fugger L, Strominger J, Siebold C . MHC class II proteins and disease: a structural perspective. Nat Rev Immunol. 2006; 6(4):271-82. DOI: 10.1038/nri1805. View

11.

Amicosante M, Sanarico N, Berretta F, Arroyo J, Lombardi G, Lechler R . Beryllium binding to HLA-DP molecule carrying the marker of susceptibility to berylliosis glutamate beta 69. Hum Immunol. 2001; 62(7):686-93. DOI: 10.1016/s0198-8859(01)00261-0. View

12.

Amicosante M, Berretta F, Dweik R, Saltini C . Role of high-affinity HLA-DP specific CLIP-derived peptides in beryllium binding to the HLA-DPGlu69 berylliosis-associated molecules and presentation to beryllium-sensitized T cells. Immunology. 2009; 128(1 Suppl):e462-70. PMC: 2753961. DOI: 10.1111/j.1365-2567.2008.03000.x. View

13.

Snyder J, Weston A, Tinkle S, Demchuk E . Electrostatic potential on human leukocyte antigen: implications for putative mechanism of chronic beryllium disease. Environ Health Perspect. 2003; 111(15):1827-34. PMC: 1241746. DOI: 10.1289/ehp.6327. View

14.

Maier L, McGrath D, Sato H, Lympany P, Welsh K, du Bois R . Influence of MHC class II in susceptibility to beryllium sensitization and chronic beryllium disease. J Immunol. 2003; 171(12):6910-8. DOI: 10.4049/jimmunol.171.12.6910. View

15.

Kreiss K, Wasserman S, Mroz M, Newman L . Beryllium disease screening in the ceramics industry. Blood lymphocyte test performance and exposure-disease relations. J Occup Med. 1993; 35(3):267-74. View

16.

Bill J, Mack D, Falta M, Maier L, Sullivan A, Joslin F . Beryllium presentation to CD4+ T cells is dependent on a single amino acid residue of the MHC class II beta-chain. J Immunol. 2005; 175(10):7029-37. DOI: 10.4049/jimmunol.175.10.7029. View

17.

Rossman M, Stubbs J, Lee C, Argyris E, Magira E, Monos D . Human leukocyte antigen Class II amino acid epitopes: susceptibility and progression markers for beryllium hypersensitivity. Am J Respir Crit Care Med. 2002; 165(6):788-94. DOI: 10.1164/ajrccm.165.6.2104002. View

18.

Kozono H, White J, Clements J, Marrack P, Kappler J . Production of soluble MHC class II proteins with covalently bound single peptides. Nature. 1994; 369(6476):151-4. DOI: 10.1038/369151a0. View

19.

Dong R, Kimura A, Okubo R, Shinagawa H, Tamai H, Nishimura Y . HLA-A and DPB1 loci confer susceptibility to Graves' disease. Hum Immunol. 1992; 35(3):165-72. DOI: 10.1016/0198-8859(92)90101-r. View

20.

Painter C, Cruz A, Lopez G, Stern L, Zavala-Ruiz Z . Model for the peptide-free conformation of class II MHC proteins. PLoS One. 2008; 3(6):e2403. PMC: 2408972. DOI: 10.1371/journal.pone.0002403. View